Back to Search
Start Over
Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report
- Source :
- Journal of Diabetes Investigation, Vol 12, Iss 12, Pp 2263-2266 (2021), Journal of Diabetes Investigation
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- Diabetes is a rare, but potentially life‐threatening, adverse event of immune checkpoint inhibitors that requires prompt recognition and treatment. It usually occurs in the first 3 months of treatment and is typically related to programmed cell death‐1 antibodies, alone or in combined therapy. It has rarely been described developing after immunotherapy cessation. We present a 51‐year‐old man with metastatic melanoma, who developed acute‐onset diabetes 52 days after combined immunotherapy cessation with nivolumab and ipilimumab, and 25.6 months after receiving the first dose. He presented with acute hyperglycemic symptoms, ketosis, complete insulin depletion and negative autoimmunity, fulfilling the criteria of fulminant type 1 diabetes. The patient had previously developed hypophysitis with isolated adrenocorticotropic hormone deficiency during immunotherapy. We describe a case of late‐onset fulminant type 1 diabetes developing after immunotherapy cessation. Patient education and active follow up after immunotherapy discontinuation are crucial to warrant a timely intervention.<br />We describe a case of immunotherapy‐related type 1 diabetes developing after combined immunotherapy cessation. The patient developed fulminant type 1 diabetes >2 years after the first immunotherapy dose, and had previously developed immune‐related hypophysitis.
- Subjects :
- Pediatrics
medicine.medical_specialty
Hypophysitis
Endocrinology, Diabetes and Metabolism
Fulminant
medicine.medical_treatment
Case Report
Ipilimumab
Diseases of the endocrine glands. Clinical endocrinology
Diabetes mellitus
Internal Medicine
medicine
Type 1 diabetes
Fulminant type 1 diabetes
business.industry
Articles
General Medicine
Immunotherapy
medicine.disease
RC648-665
Discontinuation
Clinical Science and Care
Nivolumab
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 20401116 and 20401124
- Volume :
- 12
- Issue :
- 12
- Database :
- OpenAIRE
- Journal :
- Journal of Diabetes Investigation
- Accession number :
- edsair.doi.dedup.....467da214e075360c320c9a0f1c960958